Novartis set to buy Avidity Biosciences for more than $10bn ○
found
a story from Financial Times ✅ › Financial Times
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Avidity Biosciences
since
auto-detected in 2 stories
4 months ago
Deal would be biggest acquisition under chief executive Vas Narasimhan
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports ⊕
found
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
page 1 of 1